WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China, has entered into a three-year strategic research cooperation agreement with Germany’s Medigene AG, an immuno-oncology platform company. The collaboration focuses on the design and research of T-cell receptor (TCR) mediated T cell engagers (TCEs) aimed at targeting refractory tumors. Financial terms of the agreement were not disclosed.
This partnership will harness Medigene’s advanced capabilities in TCR generation and characterization, known for their sensitivity, specificity, and safety. WuXi Biologics will contribute its proprietary CD3 antibody, along with its industry-leading TCE technology platform and patented dual antibody technology, to expedite the development of therapies for refractory tumors.- Flcube.com
